Market research
4550.TSE Nissui Pharmaceutical Co., Ltd
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7K
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 1.7%
- Beta
- -0.22
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- JP3678100003
- Market cap
- 7K
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- 1.7%
- Beta
- -0.22
About
About Nissui Pharmaceutical Co., Ltd
Nissui Pharmaceutical Co., Ltd. produces, sells, imports, and exports culture media and diagnostics for medical institutions, research organizations, and food industries in Japan and internationally. It offers in vitro diagnostics and medical devices; culture media for microbiological testing; products for antimicrobial susceptibility tests, microorganism identification, and immunological tests; and quality control serum, which is used for ensuring the accuracy of clinical diagnoses. In addition,, the company provides microbiological testing products for food poisoning detection; immunosorbent assays for the detection of allergies to food items, such as eggs, wheat, milk, shrimp, crabs, buckwheat, peanuts, etc.; and culture media and reagents for regenerative medicine. Further, it supplies testing agents and bulk products to diagnostic agent manufacturers; and CompactDry, a dry medium that is used for coliform counting for food manufacturers. The company was formerly known as Nissan Research Institute Co., Ltd. and changed its name to Nissui Pharmaceutical Co., Ltd. in 1962. Nissui Pharmaceutical Co., Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4550.TSE discussion.
5 years, 6 months ago
Nissui Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 1.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Nissui Pharmaceutical Co., Ltd's total revenue rose by 13.2% to $3B since the same quarter in the previous year.
Its net income has increased by 7.8% to $194M since the same quarter in the previous year.
Based on the above factors, Nissui Pharmaceutical Co., Ltd gets an overall score of 3/5.